Key result
Ablation beyond PVI shows no additional clinical benefit for persistent AF.
This review highlights the ongoing controversies and technological advancements in catheter ablation strategies for persistent atrial fibrillation, noting the lack of proven benefit for substrate modification beyond pulmonary vein isolation.
Supports PVI alone for persistent AF; leaves open whether novel technologies will alter outcomes in future trials.
肺静脉隔离是房颤消融的基石，然而对于持续性房颤疗效欠佳，尽管目前专家共识均认为持续性房颤消融有必要在肺静脉隔离的基础上进一步进行心房基质改良，但目前的随机对照试验并没有证实肺静脉以外的消融策略可以带来临床获益。随着导管消融技术的进步以及心律失常介入器械的研发，持续性房颤导管消融策略在争议与创新中不断发展进步，本文将针对目前持续性房颤消融技术的进展与争议进行述评。.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied this question. Ablation strategies extending beyond pulmonary vein isolation have not demonstrated additional clinical benefit for persistent atrial fibrillation in current randomized controlled trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: